How to take Pazopanib

The recommended dose of Pazopanib is 800 mg (four 200 mg tablets) once daily without food or at least 1 hour before or 2 hours after a meal until disease progression or unacceptable toxicity occurs. Do not crush tablets as this may increase absorption, thereby affecting systemic exposure.

If patients experience adverse reactions during treatment with pazopanib, the dose should be adjusted under the guidance of a doctor. For patients with renal cell carcinoma, the dose is reduced to 400 mg orally once a day for the first time, and to 200 mg orally once a day for the second time; for patients with soft tissue sarcoma, the dose is reduced to 600 mg orally once a day for the first time, and to 400 mg orally once a day for the second time. Pazopanib should be permanently discontinued in patients who are unable to tolerate the second dose reduction.

For patients with moderate hepatic impairment[total bilirubin >1.5-3 times the upper limit of normal (ULN) and any alanine aminotransferase (ALT) value], consider alternatives to pazopanib. If pazopanib is used in patients with moderate hepatic impairment, reduce the oral dose to 200 mg once daily. Pazopanib is not recommended in patients with severe hepatic impairment (total bilirubin >3 × ULN and any ALT value).

If coadministration of a strongCYP3A4 inhibitor is necessary, reduce thepazopanib dose to400 mg. Pazopanib is not recommended for patients in whom long-term use of strong CYP3A4 inducers cannot be avoided. If concomitant use of acid-reducing agents cannot be avoided, consider using short-acting antacids instead of proton pump inhibitors (PPIs) and H2-receptor antagonists, spacing the administration of short-acting antacids and vitamin E by several hours.